JP2024532403A - 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ - Google Patents

腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ Download PDF

Info

Publication number
JP2024532403A
JP2024532403A JP2024513300A JP2024513300A JP2024532403A JP 2024532403 A JP2024532403 A JP 2024532403A JP 2024513300 A JP2024513300 A JP 2024513300A JP 2024513300 A JP2024513300 A JP 2024513300A JP 2024532403 A JP2024532403 A JP 2024532403A
Authority
JP
Japan
Prior art keywords
ttds
group
analog
relaxin
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532403A5 (enExample
Inventor
ギード・マーニ
Original Assignee
リバー ツー レナル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リバー ツー レナル コーポレーション filed Critical リバー ツー レナル コーポレーション
Publication of JP2024532403A publication Critical patent/JP2024532403A/ja
Publication of JP2024532403A5 publication Critical patent/JP2024532403A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024513300A 2021-08-23 2022-08-22 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ Pending JP2024532403A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US63/236,090 2021-08-23
US202263332994P 2022-04-20 2022-04-20
US63/332,994 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (2)

Publication Number Publication Date
JP2024532403A true JP2024532403A (ja) 2024-09-05
JP2024532403A5 JP2024532403A5 (enExample) 2025-08-29

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513300A Pending JP2024532403A (ja) 2021-08-23 2022-08-22 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ

Country Status (7)

Country Link
US (1) US20240400638A1 (enExample)
EP (1) EP4392440A4 (enExample)
JP (1) JP2024532403A (enExample)
AU (1) AU2022334113A1 (enExample)
CA (1) CA3229783A1 (enExample)
MX (1) MX2024002335A (enExample)
WO (1) WO2023028008A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ766762A (en) * 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001488A (es) * 2012-07-31 2015-04-08 Novartis Ag Tratamiento de la inflamacion utilizando serelaxina.
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
NZ766762A (en) * 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use

Also Published As

Publication number Publication date
US20240400638A1 (en) 2024-12-05
EP4392440A4 (en) 2025-07-30
MX2024002335A (es) 2024-05-23
AU2022334113A1 (en) 2024-03-14
WO2023028008A3 (en) 2023-10-26
EP4392440A2 (en) 2024-07-03
CA3229783A1 (en) 2023-03-02
WO2023028008A2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
JP2024532403A (ja) 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ
TWI763972B (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其醫療用途
TWI669309B (zh) 升糖素及ｇｌｐ－１共激動劑化合物
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
US9968649B2 (en) Vasopressin formulations for use in treatment of hypotension
TW201940504A (zh) 經修飾之脂質化鬆弛素ｂ鏈胜肽及其治療用途
CN111944025B (zh) 艾滋病病毒膜融合抑制剂脂肽及药物用途
US9744209B2 (en) Vasopressin formulations for use in treatment of hypotension
JP2025106397A (ja) レナラーゼアゴニスト活性を有する安定なペプチド
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
US20220133838A1 (en) Vasopressin formulations for use in treatment of hypotension
CN118510796A (zh) 用于治疗肾脏病症或疾患的松弛素和加压素类似物的组合
TW202233650A (zh) Masp抑制性化合物及其用途
CN116034159A (zh) 新型肾上腺髓质素类似物及其制备方法和医药用途
JP2005082489A6 (ja) 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド
JP2005082489A (ja) 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250821